Vrathasha Vrathasha, Nikonov Sergei, Bell Brent Allen, He Jie, Bungatavula Yajat, Uyhazi Katherine Elizabeth, Murthy Chavali Venkata Ramana
Scheie Eye Institute at The Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Center for Advanced Retinal and Ocular Therapeutics (CAROT) and F.M. Kirby Center for Molecular Ophthalmology, University of Pennsylvania, Philadelphia, PA 19104, USA.
iScience. 2022 Oct 7;25(11):105308. doi: 10.1016/j.isci.2022.105308. eCollection 2022 Nov 18.
Glaucoma is an optic neuropathy characterized by permanent visual field loss caused by the death of retinal ganglion cells (RGCs) and it is the leading cause of irreversible blindness worldwide. Consequently, there is an unmet need for the development of new strategies for its treatment. We investigated RGC replacement therapy as a treatment for ganglion cell loss. Human-induced pluripotent stem cells (hiPSCs) were differentiated into mature, functional RGCs , labeled with AAV2.7m8-SNCG-eGFP, and transplanted intravitreally in wild-type 4-month-old C57BL/6J mice. Survival of the transplanted hiPSC-RGCs was assessed by color fundus photography and histological studies confirmed the localization of the transplanted hiPSC-RGCs within the retina. Two-photon live imaging of retinal explants and electrophysiological studies confirmed that the morphology and function of the transplanted hiPSC-RGCs were similar to native RGCs. These experiments will provide key strategies to enhance the efficiency of stem cell replacement therapy for neurodegenerative diseases, including glaucoma.
青光眼是一种视神经病变,其特征是视网膜神经节细胞(RGCs)死亡导致永久性视野缺损,它是全球不可逆失明的主要原因。因此,开发新的治疗策略存在未满足的需求。我们研究了RGC替代疗法作为神经节细胞丢失的一种治疗方法。将人诱导多能干细胞(hiPSCs)分化为成熟的、有功能的RGCs,用AAV2.7m8-SNCG-eGFP标记,并通过玻璃体内注射移植到4个月大的野生型C57BL/6J小鼠体内。通过彩色眼底照相术评估移植的hiPSC-RGCs的存活情况,组织学研究证实了移植的hiPSC-RGCs在视网膜内的定位。视网膜外植体的双光子活体成像和电生理研究证实,移植的hiPSC-RGCs的形态和功能与天然RGCs相似。这些实验将为提高包括青光眼在内的神经退行性疾病的干细胞替代治疗效率提供关键策略。